pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Hysingla ER
drug
save

hydrocodone bitartrate ER

Marketedupdated 3mo ago
by Purdue Pharma LP
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • drugHYDROCODONE BITARTRATE AND ACETAMINOPHEN1,611 co-mentions · 537 sources
  • tagApproval1,516 co-mentions · 654 sources
  • drugHYDROCODONE BITARTRATE966 co-mentions · 654 sources
  • drugHYDROCODONE BITARTRATE AND IBUPROFEN966 co-mentions · 654 sources
  • tagSmall Molecule758 co-mentions · 654 sources
  • drugAdvil208 co-mentions · 104 sources
  • drugMidol208 co-mentions · 104 sources
  • drugNuprin208 co-mentions · 104 sources

all catalysts(39)

approval · 39
Nov 6, 2006
approval
20y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Apr 3, 2007
approval
19y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Dec 31, 2007
approval
19y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Apr 23, 2013
approval
13y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Apr 3, 2015
approval
11y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Apr 3, 2015
approval
11y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Jun 2, 2016
approval
10y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Aug 15, 2018
approval
8y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Sep 14, 2018
approval
8y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Sep 18, 2018
approval
8y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Sep 18, 2018
approval
8y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Sep 20, 2018
approval
8y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Sep 21, 2018
approval
8y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Jul 22, 2019
approval
7y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Jul 22, 2019
approval
7y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Oct 11, 2019
approval
7y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Oct 11, 2019
approval
7y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Jan 21, 2020
approval
7y ago
HYDROCODONE BITARTRATE — FDA approval
hydrocodone bitartrate ER
→
Mar 4, 2021
approval
5y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Mar 4, 2021
approval
5y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Apr 28, 2021
approval
5y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Apr 30, 2021
approval
5y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Sep 2, 2021
approval
5y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Dec 11, 2023
approval
3y ago
HYDROCODONE BITARTRATE — FDA approval
hydrocodone bitartrate ER
→
Dec 15, 2023
approval
3y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Dec 15, 2023
approval
3y ago
HYDROCODONE BITARTRATE — FDA approval
hydrocodone bitartrate ER
→
Dec 15, 2023
approval
3y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Dec 15, 2023
approval
3y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Dec 15, 2023
approval
3y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Oct 3, 2024
approval
2y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Oct 31, 2024
approval
2y ago
HYDROCODONE BITARTRATE — FDA approval
hydrocodone bitartrate ER
→
Oct 31, 2024
approval
2y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Oct 31, 2024
approval
2y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Nov 21, 2024
approval
2y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Nov 21, 2024
approval
2y ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Sep 26, 2025
approval
11mo ago
HYDROCODONE BITARTRATE — FDA approval
hydrocodone bitartrate ER
→
Dec 22, 2025
approval
8mo ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
Dec 22, 2025
approval
8mo ago
HYDROCODONE BITARTRATE — FDA approval
hydrocodone bitartrate ER
→
Dec 22, 2025
approval
8mo ago
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approval
hydrocodone bitartrate ER
→
view all 39 catalysts →

Trials studying hydrocodone bitartrate ER

  • phase1Study to Investigate the Safety, Tolerability and Pharmacokinetics of QEV-817 Oral Suspensionnot yet recruitingn=8

Patent cliff

source: FDA Orange Book
first barrier falls
Aug 24, 2027
~1.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (244)

  • Sep 12, 2034method-of-use (U-55)US 10092559
  • Sep 12, 2034method-of-use (U-55)US 10092559
  • Sep 12, 2034method-of-use (U-55)US 10092559
  • Sep 12, 2034method-of-use (U-55)US 10092559
  • Sep 12, 2034method-of-use (U-55)US 10092559
  • Sep 12, 2034method-of-use (U-55)US 10092559
  • Sep 12, 2034formulationUS 9132096
  • Sep 12, 2034formulationUS 9132096
  • Sep 12, 2034formulationUS 9132096
  • Sep 12, 2034formulationUS 9132096
  • Sep 12, 2034formulationUS 9132096
  • Sep 12, 2034formulationUS 9132096
  • Sep 12, 2034method-of-use (U-55)US 9452163
  • Sep 12, 2034method-of-use (U-55)US 9452163
  • Sep 12, 2034method-of-use (U-55)US 9452163
  • Sep 12, 2034method-of-use (U-55)US 9452163
  • Sep 12, 2034method-of-use (U-55)US 9452163
  • Sep 12, 2034method-of-use (U-55)US 9452163
  • Sep 12, 2034method-of-use (U-55)US 9486451
  • Sep 12, 2034method-of-use (U-55)US 9486451
  • Sep 12, 2034method-of-use (U-55)US 9486451
  • Sep 12, 2034method-of-use (U-55)US 9486451
  • Sep 12, 2034method-of-use (U-55)US 9486451
  • Sep 12, 2034method-of-use (U-55)US 9486451
  • Sep 12, 2034formulationUS 9713611
  • Sep 12, 2034formulationUS 9713611
  • Sep 12, 2034formulationUS 9713611
  • Sep 12, 2034formulationUS 9713611
  • Sep 12, 2034formulationUS 9713611
  • Sep 12, 2034formulationUS 9713611
  • Jul 25, 2033method-of-use (U-1810)US 10028946
  • Jul 25, 2033method-of-use (U-1810)US 10028946
  • Jul 25, 2033method-of-use (U-1810)US 10028946
  • Jul 25, 2033method-of-use (U-1810)US 10028946
  • Jul 25, 2033method-of-use (U-1810)US 10028946
  • Jul 25, 2033method-of-use (U-1810)US 10028946
  • Jul 25, 2033formulationUS 10322120
  • Jul 25, 2033formulationUS 10322120
  • Jul 25, 2033formulationUS 10322120
  • Jul 25, 2033formulationUS 10322120
  • Jul 25, 2033formulationUS 10322120
  • Jul 25, 2033formulationUS 10322120
  • Jul 25, 2033method-of-use (U-1810)US 10456393
  • Jul 25, 2033method-of-use (U-1810)US 10456393
  • Jul 25, 2033method-of-use (U-1810)US 10456393
  • Jul 25, 2033method-of-use (U-1810)US 10456393
  • Jul 25, 2033method-of-use (U-1810)US 10456393
  • Jul 25, 2033method-of-use (U-1810)US 10456393
  • Jul 25, 2033method-of-use (U-1810)US 10722511
  • Jul 25, 2033method-of-use (U-1810)US 10722511
  • Jul 25, 2033method-of-use (U-1810)US 10722511
  • Jul 25, 2033method-of-use (U-1810)US 10722511
  • Jul 25, 2033method-of-use (U-1810)US 10722511
  • Jul 25, 2033method-of-use (U-1810)US 10722511
  • Jul 25, 2033method-of-use (U-1810)US 9265760
  • Jul 25, 2033method-of-use (U-1810)US 9265760
  • Jul 25, 2033method-of-use (U-1810)US 9265760
  • Jul 25, 2033method-of-use (U-1810)US 9265760
  • Jul 25, 2033method-of-use (U-1810)US 9265760
  • Jul 25, 2033method-of-use (U-1810)US 9265760
  • Jul 25, 2033method-of-use (U-1810)US 9326982
  • Jul 25, 2033method-of-use (U-1810)US 9326982
  • Jul 25, 2033method-of-use (U-1810)US 9326982
  • Jul 25, 2033method-of-use (U-1810)US 9326982
  • Jul 25, 2033method-of-use (U-1810)US 9326982
  • Jul 25, 2033method-of-use (U-1810)US 9326982
  • Jul 25, 2033method-of-use (U-1810)US 9333201
  • Jul 25, 2033method-of-use (U-1810)US 9333201
  • Jul 25, 2033method-of-use (U-1810)US 9333201
  • Jul 25, 2033method-of-use (U-1810)US 9333201
  • Jul 25, 2033method-of-use (U-1810)US 9333201
  • Jul 25, 2033method-of-use (U-1810)US 9333201
  • Jul 25, 2033method-of-use (U-1810)US 9339499
  • Jul 25, 2033method-of-use (U-1810)US 9339499
  • Jul 25, 2033method-of-use (U-1810)US 9339499
  • Jul 25, 2033method-of-use (U-1810)US 9339499
  • Jul 25, 2033method-of-use (U-1810)US 9339499
  • Jul 25, 2033method-of-use (U-1810)US 9339499
  • Jul 25, 2033method-of-use (U-1810)US 9421200
  • Jul 25, 2033method-of-use (U-1810)US 9421200
  • Jul 25, 2033method-of-use (U-1810)US 9421200
  • Jul 25, 2033method-of-use (U-1810)US 9421200
  • Jul 25, 2033method-of-use (U-1810)US 9421200
  • Jul 25, 2033method-of-use (U-1810)US 9421200
  • Jul 25, 2033method-of-use (U-1810)US 9433619
  • Jul 25, 2033method-of-use (U-1810)US 9433619
  • Jul 25, 2033method-of-use (U-1810)US 9433619
  • Jul 25, 2033method-of-use (U-1810)US 9433619
  • Jul 25, 2033method-of-use (U-1810)US 9433619
  • Jul 25, 2033method-of-use (U-1810)US 9433619
  • Jul 25, 2033method-of-use (U-1810)US 9610286
  • Jul 25, 2033method-of-use (U-1810)US 9610286
  • Jul 25, 2033method-of-use (U-1810)US 9610286
  • Jul 25, 2033method-of-use (U-1810)US 9610286
  • Jul 25, 2033method-of-use (U-1810)US 9610286
  • Jul 25, 2033method-of-use (U-1810)US 9610286
  • Dec 21, 2031formulationUS 8808740
  • Dec 21, 2031formulationUS 8808740
  • Dec 21, 2031formulationUS 8808740
  • Dec 21, 2031formulationUS 8808740
  • Dec 21, 2031formulationUS 8808740
  • Dec 21, 2031formulationUS 8808740
  • Dec 21, 2031formulationUS 8808740
  • Dec 21, 2031formulationUS 9572779
  • Dec 21, 2031formulationUS 9572779
  • Dec 21, 2031formulationUS 9572779
  • Dec 21, 2031formulationUS 9572779
  • Dec 21, 2031formulationUS 9572779
  • Dec 21, 2031formulationUS 9572779
  • Dec 21, 2031formulationUS 9572779
  • Dec 21, 2031formulationUS 9750703
  • Dec 21, 2031formulationUS 9750703
  • Dec 21, 2031formulationUS 9750703
  • Dec 21, 2031formulationUS 9750703
  • Dec 21, 2031formulationUS 9750703
  • Dec 21, 2031formulationUS 9750703
  • Dec 21, 2031formulationUS 9750703
  • Dec 21, 2031formulationUS 9861584
  • Dec 21, 2031formulationUS 9861584
  • Dec 21, 2031formulationUS 9861584
  • Dec 21, 2031formulationUS 9861584
  • Dec 21, 2031formulationUS 9861584
  • Dec 21, 2031formulationUS 9861584
  • Dec 21, 2031formulationUS 9861584
  • Dec 21, 2031formulationUS 9872837
  • Dec 21, 2031formulationUS 9872837
  • Dec 21, 2031formulationUS 9872837
  • Dec 21, 2031formulationUS 9872837
  • Dec 21, 2031formulationUS 9872837
  • Dec 21, 2031formulationUS 9872837
  • Dec 21, 2031formulationUS 9872837
  • Jul 31, 2029formulationUS 84450182.9y
  • Jul 31, 2029formulationUS 84450182.9y
  • Jul 31, 2029formulationUS 84450182.9y
  • Jul 31, 2029formulationUS 84450182.9y
  • Jul 31, 2029formulationUS 84450182.9y
  • Sep 13, 2027formulationUS 92161761.1y
  • Sep 13, 2027formulationUS 92161761.1y
  • Sep 13, 2027formulationUS 92161761.1y
  • Sep 13, 2027formulationUS 92161761.1y
  • Sep 13, 2027formulationUS 92161761.1y
  • Sep 13, 2027formulationUS 95728031.1y
  • Sep 13, 2027formulationUS 95728031.1y
  • Sep 13, 2027formulationUS 95728031.1y
  • Sep 13, 2027formulationUS 95728031.1y
  • Sep 13, 2027formulationUS 95728031.1y
  • Aug 24, 2027formulationUS 113049081.0y
  • Aug 24, 2027formulationUS 113049081.0y
  • Aug 24, 2027formulationUS 113049081.0y
  • Aug 24, 2027formulationUS 113049081.0y
  • Aug 24, 2027formulationUS 113049081.0y
  • Aug 24, 2027formulationUS 113049081.0y
  • Aug 24, 2027formulationUS 113049081.0y
  • Aug 24, 2027method-of-use (U-1556)US 113049091.0y
  • Aug 24, 2027method-of-use (U-1556)US 113049091.0y
  • Aug 24, 2027method-of-use (U-1556)US 113049091.0y
  • Aug 24, 2027method-of-use (U-1556)US 113049091.0y
  • Aug 24, 2027method-of-use (U-1556)US 113049091.0y
  • Aug 24, 2027method-of-use (U-1556)US 113049091.0y
  • Aug 24, 2027method-of-use (U-1556)US 113049091.0y
  • Aug 24, 2027formulationUS 90848161.0y
  • Aug 24, 2027formulationUS 90848161.0y
  • Aug 24, 2027formulationUS 90848161.0y
  • Aug 24, 2027formulationUS 90848161.0y
  • Aug 24, 2027formulationUS 90848161.0y
  • Aug 24, 2027formulationUS 90848161.0y
  • Aug 24, 2027formulationUS 90848161.0y
  • Aug 24, 2027method-of-use (U-1556)US 90956141.0y
  • Aug 24, 2027method-of-use (U-1556)US 90956141.0y
  • Aug 24, 2027method-of-use (U-1556)US 90956141.0y
  • Aug 24, 2027method-of-use (U-1556)US 90956141.0y
  • Aug 24, 2027method-of-use (U-1556)US 90956141.0y
  • Aug 24, 2027method-of-use (U-1556)US 90956141.0y
  • Aug 24, 2027method-of-use (U-1556)US 90956141.0y
  • Aug 24, 2027formulationUS 90956151.0y
  • Aug 24, 2027formulationUS 90956151.0y
  • Aug 24, 2027formulationUS 90956151.0y
  • Aug 24, 2027formulationUS 90956151.0y
  • Aug 24, 2027formulationUS 90956151.0y
  • Aug 24, 2027formulationUS 90956151.0y
  • Aug 24, 2027formulationUS 90956151.0y
  • Aug 24, 2027formulationUS 94864121.0y
  • Aug 24, 2027formulationUS 94864121.0y
  • Aug 24, 2027formulationUS 94864121.0y
  • Aug 24, 2027formulationUS 94864121.0y
  • Aug 24, 2027formulationUS 94864121.0y
  • Aug 24, 2027formulationUS 94864121.0y
  • Aug 24, 2027formulationUS 94864121.0y
  • Aug 24, 2027formulationUS 94864131.0y
  • Aug 24, 2027formulationUS 94864131.0y
  • Aug 24, 2027formulationUS 94864131.0y
  • Aug 24, 2027formulationUS 94864131.0y
  • Aug 24, 2027formulationUS 94864131.0y
  • Aug 24, 2027formulationUS 94864131.0y
  • Aug 24, 2027formulationUS 94864131.0y
  • Aug 24, 2027formulationUS 94923891.0y
  • Aug 24, 2027formulationUS 94923891.0y
  • Aug 24, 2027formulationUS 94923891.0y
  • Aug 24, 2027formulationUS 94923891.0y
  • Aug 24, 2027formulationUS 94923891.0y
  • Aug 24, 2027formulationUS 94923891.0y
  • Aug 24, 2027formulationUS 94923891.0y
  • Aug 24, 2027method-of-use (U-1556)US 94923901.0y
  • Aug 24, 2027method-of-use (U-1556)US 94923901.0y
  • Aug 24, 2027method-of-use (U-1556)US 94923901.0y
  • Aug 24, 2027method-of-use (U-1556)US 94923901.0y
  • Aug 24, 2027method-of-use (U-1556)US 94923901.0y
  • Aug 24, 2027method-of-use (U-1556)US 94923901.0y
  • Aug 24, 2027method-of-use (U-1556)US 94923901.0y
  • Aug 24, 2027method-of-use (U-1556)US 94923911.0y
  • Aug 24, 2027method-of-use (U-1556)US 94923911.0y
  • Aug 24, 2027method-of-use (U-1556)US 94923911.0y
  • Aug 24, 2027method-of-use (U-1556)US 94923911.0y
  • Aug 24, 2027method-of-use (U-1556)US 94923911.0y
  • Aug 24, 2027method-of-use (U-1556)US 94923911.0y
  • Aug 24, 2027method-of-use (U-1556)US 94923911.0y
  • Aug 24, 2027method-of-use (U-1556)US 95453801.0y
  • Aug 24, 2027method-of-use (U-1556)US 95453801.0y
  • Aug 24, 2027method-of-use (U-1556)US 95453801.0y
  • Aug 24, 2027method-of-use (U-1556)US 95453801.0y
  • Aug 24, 2027method-of-use (U-1556)US 95453801.0y
  • Aug 24, 2027method-of-use (U-1556)US 95453801.0y
  • Aug 24, 2027method-of-use (U-1556)US 95453801.0y
  • Aug 24, 2027formulationUS 97639331.0y
  • Aug 24, 2027formulationUS 97639331.0y
  • Aug 24, 2027formulationUS 97639331.0y
  • Aug 24, 2027formulationUS 97639331.0y
  • Aug 24, 2027formulationUS 97639331.0y
  • Aug 24, 2027formulationUS 97639331.0y
  • Aug 24, 2027formulationUS 97639331.0y
  • Aug 24, 2027formulationUS 97704161.0y
  • Aug 24, 2027formulationUS 97704161.0y
  • Aug 24, 2027formulationUS 97704161.0y
  • Aug 24, 2027formulationUS 97704161.0y
  • Aug 24, 2027formulationUS 97704161.0y
  • Aug 24, 2027formulationUS 97704161.0y
  • Aug 24, 2027formulationUS 97704161.0y
  • Aug 24, 2027formulationUS 97758091.0y
  • Aug 24, 2027formulationUS 97758091.0y
  • Aug 24, 2027formulationUS 97758091.0y
  • Aug 24, 2027formulationUS 97758091.0y
  • Aug 24, 2027formulationUS 97758091.0y
  • Aug 24, 2027formulationUS 97758091.0y
  • Aug 24, 2027formulationUS 97758091.0y

News(0)

no news has mentioned this drug yet

brand
Hysingla ER
generic
hydrocodone bitartrate
indication
Pain
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 34m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?